
Epiproteomics Could Advance Biomarker Discovery and Patient Care
For complex chronic diseases, from autoimmune disorders to neurodegeneration, too many clinical decisions still rely on trial and error. Drug development fares no better, often hindered by late-stage failures and imprecise targeting. At the heart of this …